Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 103

1.

Effect of aspirin or resistant starch on colorectal neoplasia in the Lynch syndrome.

Burn J, Bishop DT, Mecklin JP, Macrae F, Möslein G, Olschwang S, Bisgaard ML, Ramesar R, Eccles D, Maher ER, Bertario L, Jarvinen HJ, Lindblom A, Evans DG, Lubinski J, Morrison PJ, Ho JW, Vasen HF, Side L, Thomas HJ, Scott RJ, Dunlop M, Barker G, Elliott F, Jass JR, Fodde R, Lynch HT, Mathers JC; CAPP2 Investigators.

N Engl J Med. 2008 Dec 11;359(24):2567-78. doi: 10.1056/NEJMoa0801297. Erratum in: N Engl J Med. 2009 Apr 2;360(14):1470.

2.

Effect of aspirin or resistant starch on colorectal neoplasia in the Lynch syndrome.

Yang F, Jin C, Fu D.

N Engl J Med. 2009 Apr 2;360(14):1461-2; author reply 1462-3. doi: 10.1056/NEJMc090032. No abstract available.

3.

Long-term effect of aspirin on cancer risk in carriers of hereditary colorectal cancer: an analysis from the CAPP2 randomised controlled trial.

Burn J, Gerdes AM, Macrae F, Mecklin JP, Moeslein G, Olschwang S, Eccles D, Evans DG, Maher ER, Bertario L, Bisgaard ML, Dunlop MG, Ho JW, Hodgson SV, Lindblom A, Lubinski J, Morrison PJ, Murday V, Ramesar R, Side L, Scott RJ, Thomas HJ, Vasen HF, Barker G, Crawford G, Elliott F, Movahedi M, Pylvanainen K, Wijnen JT, Fodde R, Lynch HT, Mathers JC, Bishop DT; CAPP2 Investigators.

Lancet. 2011 Dec 17;378(9809):2081-7. doi: 10.1016/S0140-6736(11)61049-0. Epub 2011 Oct 27.

4.

Effect of aspirin or resistant starch on colorectal neoplasia in the Lynch syndrome.

Topping DL, Bird AR, Young GP.

N Engl J Med. 2009 Apr 2;360(14):1462; author reply 1462-3. No abstract available.

PMID:
19348022
5.

Genetics, inheritance and strategies for prevention in populations at high risk of colorectal cancer (CRC).

Burn J, Mathers J, Bishop DT.

Recent Results Cancer Res. 2013;191:157-83. doi: 10.1007/978-3-642-30331-9_9. Review.

PMID:
22893205
6.

Long-term effect of resistant starch on cancer risk in carriers of hereditary colorectal cancer: an analysis from the CAPP2 randomised controlled trial.

Mathers JC, Movahedi M, Macrae F, Mecklin JP, Moeslein G, Olschwang S, Eccles D, Evans G, Maher ER, Bertario L, Bisgaard ML, Dunlop M, Ho JW, Hodgson S, Lindblom A, Lubinski J, Morrison PJ, Murday V, Ramesar R, Side L, Scott RJ, Thomas HJ, Vasen H, Gerdes AM, Barker G, Crawford G, Elliott F, Pylvanainen K, Wijnen J, Fodde R, Lynch H, Bishop DT, Burn J; CAPP2 Investigators.

Lancet Oncol. 2012 Dec;13(12):1242-9. doi: 10.1016/S1470-2045(12)70475-8. Epub 2012 Nov 7.

7.

Folic acid for the prevention of colorectal adenomas: a randomized clinical trial.

Cole BF, Baron JA, Sandler RS, Haile RW, Ahnen DJ, Bresalier RS, McKeown-Eyssen G, Summers RW, Rothstein RI, Burke CA, Snover DC, Church TR, Allen JI, Robertson DJ, Beck GJ, Bond JH, Byers T, Mandel JS, Mott LA, Pearson LH, Barry EL, Rees JR, Marcon N, Saibil F, Ueland PM, Greenberg ER; Polyp Prevention Study Group.

JAMA. 2007 Jun 6;297(21):2351-9.

PMID:
17551129
8.

Chemoprevention in Lynch syndrome.

Burn J, Mathers JC, Bishop DT.

Fam Cancer. 2013 Dec;12(4):707-18. doi: 10.1007/s10689-013-9650-y.

PMID:
23880960
9.

Obesity, Aspirin, and Risk of Colorectal Cancer in Carriers of Hereditary Colorectal Cancer: A Prospective Investigation in the CAPP2 Study.

Movahedi M, Bishop DT, Macrae F, Mecklin JP, Moeslein G, Olschwang S, Eccles D, Evans DG, Maher ER, Bertario L, Bisgaard ML, Dunlop MG, Ho JW, Hodgson SV, Lindblom A, Lubinski J, Morrison PJ, Murday V, Ramesar RS, Side L, Scott RJ, Thomas HJ, Vasen HF, Burn J, Mathers JC.

J Clin Oncol. 2015 Nov 1;33(31):3591-7. doi: 10.1200/JCO.2014.58.9952. Epub 2015 Aug 17.

PMID:
26282643
10.

Nonsteroidal anti-inflammatory drug use after 3 years of aspirin use and colorectal adenoma risk: observational follow-up of a randomized study.

Grau MV, Sandler RS, McKeown-Eyssen G, Bresalier RS, Haile RW, Barry EL, Ahnen DJ, Gui J, Summers RW, Baron JA.

J Natl Cancer Inst. 2009 Feb 18;101(4):267-76. doi: 10.1093/jnci/djn484. Epub 2009 Feb 10.

11.

Aspirin for the chemoprevention of colorectal adenomas: meta-analysis of the randomized trials.

Cole BF, Logan RF, Halabi S, Benamouzig R, Sandler RS, Grainge MJ, Chaussade S, Baron JA.

J Natl Cancer Inst. 2009 Feb 18;101(4):256-66. doi: 10.1093/jnci/djn485. Epub 2009 Feb 10.

PMID:
19211452
13.

A randomized trial of aspirin to prevent colorectal adenomas in patients with previous colorectal cancer.

Sandler RS, Halabi S, Baron JA, Budinger S, Paskett E, Keresztes R, Petrelli N, Pipas JM, Karp DD, Loprinzi CL, Steinbach G, Schilsky R.

N Engl J Med. 2003 Mar 6;348(10):883-90. Erratum in: N Engl J Med. 2003 May 8;348(19):1939.

14.

A randomized trial of aspirin to prevent colorectal adenomas.

Baron JA, Cole BF, Sandler RS, Haile RW, Ahnen D, Bresalier R, McKeown-Eyssen G, Summers RW, Rothstein R, Burke CA, Snover DC, Church TR, Allen JI, Beach M, Beck GJ, Bond JH, Byers T, Greenberg ER, Mandel JS, Marcon N, Mott LA, Pearson L, Saibil F, van Stolk RU.

N Engl J Med. 2003 Mar 6;348(10):891-9.

15.

Celecoxib for the prevention of sporadic colorectal adenomas.

Bertagnolli MM, Eagle CJ, Zauber AG, Redston M, Solomon SD, Kim K, Tang J, Rosenstein RB, Wittes J, Corle D, Hess TM, Woloj GM, Boisserie F, Anderson WF, Viner JL, Bagheri D, Burn J, Chung DC, Dewar T, Foley TR, Hoffman N, Macrae F, Pruitt RE, Saltzman JR, Salzberg B, Sylwestrowicz T, Gordon GB, Hawk ET; APC Study Investigators.

N Engl J Med. 2006 Aug 31;355(9):873-84.

16.

RE: Aspirin, Ibuprofen, and the Risk for Colorectal Cancer in Lynch Syndrome.

Tuccori M, Filion KB, Azoulay L.

J Natl Cancer Inst. 2015 Dec 27;108(2). pii: djv384. doi: 10.1093/jnci/djv384. Print 2016 Feb. No abstract available.

PMID:
26711870
17.

Prevalence of adenomas and hyperplastic polyps in mismatch repair mutation carriers among CAPP2 participants: report by the colorectal adenoma/carcinoma prevention programme 2.

Liljegren A, Barker G, Elliott F, Bertario L, Bisgaard ML, Eccles D, Evans G, Macrae F, Maher E, Lindblom A, Rotstein S, Nilsson B, Mecklin JP, Möslein G, Jass J, Fodde R, Mathers J, Burn J, Bishop DT.

J Clin Oncol. 2008 Jul 10;26(20):3434-9. doi: 10.1200/JCO.2007.13.2795.

18.

A Trial of Calcium and Vitamin D for the Prevention of Colorectal Adenomas.

Baron JA, Barry EL, Mott LA, Rees JR, Sandler RS, Snover DC, Bostick RM, Ivanova A, Cole BF, Ahnen DJ, Beck GJ, Bresalier RS, Burke CA, Church TR, Cruz-Correa M, Figueiredo JC, Goodman M, Kim AS, Robertson DJ, Rothstein R, Shaukat A, Seabrook ME, Summers RW.

N Engl J Med. 2015 Oct 15;373(16):1519-30. doi: 10.1056/NEJMoa1500409.

19.

Interaction of calcium supplementation and nonsteroidal anti-inflammatory drugs and the risk of colorectal adenomas.

Grau MV, Baron JA, Barry EL, Sandler RS, Haile RW, Mandel JS, Cole BF.

Cancer Epidemiol Biomarkers Prev. 2005 Oct;14(10):2353-8.

20.

Effect of combined folic acid, vitamin B(6), and vitamin B(12) on colorectal adenoma.

Song Y, Manson JE, Lee IM, Cook NR, Paul L, Selhub J, Giovannucci E, Zhang SM.

J Natl Cancer Inst. 2012 Oct 17;104(20):1562-75. doi: 10.1093/jnci/djs370. Epub 2012 Oct 12.

Supplemental Content

Support Center